Royalty Report: Drugs, Antibody, Cancer – Collection: 275845

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Antibody
  • Cancer
  • Drug Discovery
  • Therapeutic
  • Autoimmune
  • Disease
  • Immune
  • HIV / AIDs
  • Genome
  • cardiac
  • Alzheimer’s disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275845

License Grant
Licensor grants to Swiss Licensee and to Licensee’s Affiliates, during the Commercialization Term, the exclusive (even as to Licensor) right and license under the Licensor Know-How and Licensor Patents to (i) market, promote, and detail Nutley Dac in the Licensee Territory solely for use in Transplant Induction, and (ii) to sell and offer for sale Nutley Dac in the Licensee Territory under the Trademarks. In addition, Licensor grants to Licensee and to Licensee’s Affiliates, the nonexclusive right under the Licensor Know-How and Licensor Patents to make, have made, use and import Nutley Dac, but only to the extent reasonably necessary for Licensee to carry out its rights and obligations under this Second Amended and Restated Worldwide Agreement. Licensee may sublicense the rights and licenses granted to Licensee, subject to Licensor’s written consent, which consent Licensor may not unreasonably withhold. It shall be deemed reasonable for Licensor to withhold consent with respect to sublicense by Licensee of any of the rights or licenses to any other entity that is developing (in at least one Phase II clinical trial with directional human efficacy data), or marketing or selling in a Major Country any product for the treatment of any Autoimmune Indication. Notwithstanding the preceding sentence, Licensee and its Affiliates may use Third Party distributors in accordance with their customary practices. All sublicenses granted by Licensee or its Affiliates of the licenses set forth in this agreement shall automatically terminate at the end of the Commercialization Term.
License Property
Nutley Dac shall mean the FDA-approved form of Daclizumab manufactured at Licensee’s Nutley, New Jersey facility as of the Amendment Effective Date.

Daclizumab shall be deemed to be a Licensed Product, a humanized antibody now known by the generic name daclizumab, which binds to the interleukin-2 receptor (“IL-2R”). Daclizumab means any product that contains humanized anti-Tac (as defined under Field).

Licensor Patent Rights
Patent No. 5,585,089, “Humanized Immunoglobulins,” issued December 17, 1996.
Patent No. 5,693,761, “Polynucleotides Encoding Improved Humanized Immunoglobulins,” issued December 2, 1997.
Patent No. 5,693,762, “Humanized Immunoglobulins,” issued December 2, 1997.
Patent No. 6,180,370 “Humanized Immunoglobulins and Method of Making the Same”, issued January 30, 2001.

Trademarks means the trademark “Zenapax®,” and all trademark registrations and applications therefor, and all goodwill associated therewith, and all other trademarks owned by Licensee (except for any Licensee housemarks or trade names) and used in connection with the sale or promotion of Nutley Dac in the Licensee Territory.

Licensee Owned Patents means all patent applications owned by Licensee or its Affiliates (“Sole Licensee Patents”) alone or with a Third Party, and all patent applications resulting from Joint Inventions (“Joint Licensee-Licensor Patents”) covering inventions in the Field that are filed prior to or during the term of this Second Amended and Restated Worldwide Agreement in the United States or any foreign jurisdiction, including any addition, continuation, continuation-in-part or division thereof or any substitute application therefor; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other United States or foreign patent or inventor’s certificate covering inventions in the Field. Licensee Owned Patents as of the Effective Date are, specifically, those listed.
Serial No. 60/416,302 – Use of IL-2 Receptor Antibodies

Joint Inventions means any inventions in the Field, whether patented or not, that are jointly made during the period beginning on January 31, 1989 and continuing until the end of the Commercialization Term by at least one (1) Licensor employee or person contractually required to assign or license patent rights covering such inventions to Licensor and at least one (1) Licensee-Nutley or Licensee employee or person contractually required to assign or license patent rights covering such inventions to Licensee-Nutley or Licensee.

Field of Use
Field means any humanized or chimeric antibody that binds to IL-2R, where “humanized” means a genetically engineered combination of a substantially human framework region and constant region, and complementarity determining regions from non-human antibodies, and where “chimeric” means a genetically engineered combination of human constant region and non-human variable region. “Antibodies in the Field” means humanized and chimeric antibodies that bind to IL-2R. It is believed that these Antibodies in the Field may be useful for therapeutic, diagnostic, imaging and similar purposes. It is understood that the Field includes, but is not limited to, that certain humanized murine monoclonal antibody prepared against the p55 component of IL-2R (“humanized anti-Tac”). Furthermore, the Field includes, but is not limited to, all improvements relating to humanized anti-Tac, including without limitation modifications in structure introduced by genetic engineering, or by chemical or enzymatic cleavage. Also included within the Field shall be alternate hosts for producing humanized anti-Tac, methods for purification, formulations incorporating humanized anti-Tac, and uses and methods of use for humanized anti-Tac in human medicine.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis.

IPSCIO Record ID: 279338

License Grant
The Swiss Licensor hereby grants to Licensee, under the Licensor Technology, Licensor Inventions, and all patents claiming Licensor Inventions, (i) a co-exclusive license (together with Licensor) to develop in accordance with the Asthma Development Plan and Transplant Development Plan and use Licensed Products in the Collaborative Fields with respect to U.S. Territory and the European Union, (ii) a co-exclusive license (together with Licensor) to import Licensed Products in the Collaborative Fields into the European Union for such Development purposes, (iii) an exclusive license to import, offer for sale and sell Licensed Products in the Collaborative Fields in the U.S. Territory, and (iv) an exclusive license to make Licensed Products in the Collaborative Fields in the Territory.
License Property
Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab, but excluding Nutley Dac.  Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name “Daclizumab” by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.   IL-2R means the IL-2 receptor.

Licensor Inventions means all inventions that (a) relate to or are useful with antibodies that bind the IL-2 receptor (IL-2R) and (b) are made during the term of this Agreement by employees of Licensor or persons contractually required to assign or license patent rights covering such inventions to Licensor, in the course of performing Licensor’s obligations, or exercising Licensor’s rights, under this Agreement.

Field of Use
Asthma Field means the treatment and/or prevention of asthma or other respiratory diseases.

Transplant Field means the Transplant Indications.

A Collaborative Field (i.e., used in the singular) shall refer either to the Asthma Field (unless and until the Asthma Field is excluded from the definition of Collaborative Field) or the Transplant Field (unless and until the Transplant Field is excluded from· the definition of Collaborative Field.  Collaborative Fields shall be deemed to exclude the field (i.e., Asthma Field or Transplant Field) with respect to which the rights are so terminated.

IPSCIO Record ID: 319188

License Grant
Licensor hereby grants to Licensee a revenue-bearing license under the Licensor Licensed Patents and the Licensor Licensed Know-How to (1) Develop Licensed Antibodies and Products in the U.S., (2) Manufacture and use Licensed Antibodies and Products in the U.S. solely for Development purposes, (3) Commercialize, sell, offer for sale and import Products in the U.S. and (4) Manufacture and use Products in the U.S. solely for Commercialization purposes. The licenses set forth in subparts (1) and (2) above shall be co-exclusive and the licenses set forth in subparts (3) and (4) above shall be exclusive.

Licensor hereby grants to Licensee a royalty-bearing license under the Licensor Licensed Patents and the Licensor Licensed Know-How to (1) Develop Licensed Antibodies and Products in the Royalty Territory, (2) Manufacture and use Licensed Antibodies and Products in the Royalty Territory solely for Development purposes, (3) Commercialize, sell, offer for sale and import Products in the Royalty Territory and (4) Manufacture and use Products in the Royalty Territory solely for Commercialization purposes. The licenses set forth in subparts (1) and (2) above shall be co-exclusive and the licenses set forth in subparts (3) and (4) above shall be exclusive.

Licensor hereby grants to Licensee a non-exclusive license under the Queen Patents to (1) Develop Licensed Antibodies and Products in the Territory, (2) Manufacture and use Licensed Antibodies and Products in the Territory solely for Development purposes, (3) Commercialize, sell, offer for sale and import Products in the Territory and (4) Manufacture and use Products in the Territory solely for Commercialization purposes. Such license shall be revenue-bearing with respect to Products Commercialized in the U.S. and royalty-bearing with respect to Products Commercialized in the Royalty Territory.

License Property
CS1 antibodies (Target) includes antibodies known as HuLuc63 and PDL-241.

HuLuc63 means the Antibody that (i) contains the amino acid sequence set forth in this agreement and (ii) is the subject of an existing IND of Licensor prior to the Effective Date.

PDL-241 means the Antibody containing the amino acid sequence set forth in this agreement.

PDL-241 Product means any Product that contains or incorporates PDL-241.

Product means any pharmaceutical product that contains or incorporates a Licensed Antibody.

Licensed Antibody means an Existing Antibody or Future Antibody or, solely if Licensee exercises the Licensee Option, an Option Antibody.

Antibody means any (i) antibody, (ii) protein comprising at least one CDR portion thereof (including bispecific antibodies, single chain antibodies, domain antibodies and immunoconjugated antibodies) or (iii) adnectin; in each of (i), (ii) and (iii), whether human, humanized, chimeric, murine, synthetic or from any other source, that (a) has been raised, engineered or otherwise optimized to bind specifically and directly to the Target (whether exclusively or in addition to any other target such Antibody may modulate) and (b) competes for binding to the Target with a naturally occurring ligand of the Target, interferes with Target-Target interaction, or, once bound to the Target, exhibits antagonistic activity against the Target, agonist activity against the Target, ADCC (antibody dependent cellular cytotoxity) and/or other Fc-mediated effector function.

Queen Patent means any Patent that (a) is set forth in this agreement; or (b) is a continuation, divisional, continuation-in-part, substitution, extension, registration, confirmation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions or renewal of, or issues from, any Patent described in clause (a) above; or (c)  is a foreign counterpart of any of (a) or (b) above.
5,585,089 – Humanized immunoglobulins
5,693,761 – Polynucleotides encoding improved humanized immunoglobulins
5,693,762 – Humanized immunoglobulins

Licensor Licensed Patents means all Patents that are
(a) Controlled by Licensor and its Affiliates, including patents Controlled jointly with Licensee, as of the Effective Date and (i) claim a Licensed Antibody, a composition containing a Licensed Antibody (e.g., a formulation containing a Licensed Antibody), or the manufacture or use of a Licensed Antibody (or a composition containing a Licensed Antibody); or (ii) are necessary or reasonably useful for Licensee to perform its obligations to the Collaboration under the Agreement; or (b) Controlled by Licensor and its Affiliates, including Patents Controlled jointly with Licensee, during the term of this Agreement and (i) claim an Invention; or (ii) are a continuation, divisional, continuation-in-part (solely to the extent claiming subject matter disclosed in a Patent described in clause (a) above), foreign counterpart, substitution, extension, registration, confirmation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions or renewal of, or issue from, any Patent described in clause (a) above.

Notwithstanding the foregoing, Licensor Licensed Patents shall exclude (1) the Queen Patents and (2) all Patents claiming BioBetter Technology. The Licensor Licensed Patents, include, without limitation, the Patents set forth on this agreement.
5,225,539 – Recombinant altered antibodies and methods of making altered antibodies
6,548,640 Bl – Altered antibodies
5,849,522 – Enhancer for eukaryotic expression systems

Target IP means (a) U.S. Patent Nos. 7,253,256 and 7,214,777, and (b) U.S.
and ex-U.S. patents and pending patent applications that claim priority thereto, have a common
priority claim therewith or are a foreign equivalent thereof, to the extent such patents and
pending patent applications (i) claim the Target, nucleotide sequences (including vectors)
encoding the Target, host cells containing any of the foregoing, Antibodies and/or methods of
manufacturing or using any of the foregoing, or (ii) are otherwise necessary for
Commercialization of a Product.
7,253,256 – Polypeptides encoded by a nucleic acid are expressed in esophageal and kidney tumor
7,214,777 – Secreted and transmembrane polypeptides and nucleic acids encoding the same

Field of Use
The field of use is for the development of certain CS1 antibodies to be marketed for use in new therapies and treatment programs.

Licensee is a worldwide, research-based pharmaceutical company, engaged in the discovery, development, manufacturing and marketing of new therapies and treatment programs.

IPSCIO Record ID: 319172

License Grant
Licensor hereby grants to Licensee (a) through the period and subject to the limitation on the number of Antigens provided in Agreement, the right to receive for each Antigen designated by Licensee, a nonexclusive, worldwide (except as provided in this Agreement) license under the Licensor Licensed Patents to make, have made, use, import, offer to sell and sell Antibodies pursuant to a Licensor License Agreement. This right shall not extend to the Licensor Named Antigens. The rights of Licensee under the Licensor License Agreements shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable Licensor License Agreement. Each license elected by Licensee hereunder shall be pursuant to a separate Licensor License Agreement and effective as of the date of execution by both parties.
License Property
Antigen means a target molecule, usually a protein, to which an Antibody specifically binds and includes all epitopes on that target molecule.

Antibody means any antibody directed against an Antigen and shall include, without limitation, monospecific and bispecific antibodies (but a separate license shall be required for the antigen involved for each arm of a bispecific antibody); less than full-length antibody forms such as Fv, Fab, and F(ab’)2; single-chain antibodies; and antibody conjugates bound to a toxin, label or other moiety. The term “Antibody” shall include any and all such constructs directed against any particular Antigen.

Licensor Licensed Patents means the patents and patent applications identified on Exhibit B and including any applications filed as of the Original Effective Date in the United States or any foreign jurisdiction. Licensed Patents shall include U.S. or foreign patents or patent applications which claim priority to any application to which a listed U.S. patent also claims priority. Licensor Licensed Patents shall also include any foreign equivalents, addition, continuation, continuation-in-part or division of such patents or patent applications or any substitute applications therefor, any patent issued with respect to any such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent. Attached hereto as Exhibit B is a list of patents and patent applications that Licensor in good faith believes represents Licensor Licensed Patents as of the Original Effective Date.
5,693,089 – Method of collapsing an implantable appliance
5,693,761 – Polynucleotides encoding improved humanized immunoglobulins
5,693,762  – Humanized immunoglobulins

Licensor Named Antigen(s) means the following Antigens IL-12, CD3, IL-4, gamma interferon and E Selectiin.

Field of Use
The Field of use is for the development, manufacture and commercialization of antibody products directed against antigens. Antigen are target molecules which an Antibody binds to.

Licensee is a biotechnology company dedicated to discover and develop medicines for life threatening diseases such as the targeted antibody for cancer.

IPSCIO Record ID: 279345

License Grant
The English Licensor hereby grants to the English Licensee (i) a non-exclusive worldwide sublicense, with the right to grant further Sublicenses, under the Licensed Patent Rights to make, have made, use, import, offer for sale, and/or sell Licensed Products; and (ii) an exclusive worldwide license, with the right to grant Sublicenses, under the Licensor IP to make, have made, use, import, offer for sale, and/or sell Licensed Products.
License Property
US Patent #5,225,539 – Recombinant altered antibodies and methods of making altered antibodies

Licensed Product shall mean a product comprising a Humanized Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensor IP or Licensor Inventions.  The term “Licensed Product” does not include chimeric antibodies or murine antibodies.

Humanized Antibody shall mean an antibody that binds to Sphingosine-1-phosphate and is made by Licensor under this Agreement, the antibody comprising murine complementarity determining regions derived from Sphingomabâ„¢ together with human framework regions, and any modifications thereof.

Licensor IP shall mean (i) any Licensor Invention and (ii) all patented and non-patented proprietary technology and information, in any form whatsoever, that is (a) necessary or useful for making and using the Licensed Products, without regard to whether or not the technology or information is patentable; (b) owned, controlled, or developed by Licensor, as of the Effective Date or hereafter during the term of this Agreement; and (c) provided by Licensor to Licensee hereunder, including, but not limited to discoveries, formulae, materials, practices, methods, knowledge, know-how, processes, trade secrets, ideas, concepts, manufacturing, engineering, standard operating procedures, flow diagrams and charts, quality assurance, quality control data, technical data, manufacturing technology, research data and records, and all other confidential or proprietary technical and business information relating to the humanization of murine antibodies, generation of chimeric antibodies, or any gene expression vectors used in such methods and all improvements or modifications thereto.  For purposes of clarity, Licensor IP includes Licensor Inventions that satisfy (a), (b) and (c), above, while Licensor IP does not include Licensed Patent Rights as defined hereunder.

Licensor Invention shall mean any discovery or invention to the extent (i) made or conceived or reduced to practice by or on behalf of Licensor in the performance of the humanization of Licensees Sphingomabâ„¢ antibody under this Agreement, whether or not patentable, and (ii) covering only generally applicable methods or techniques for humanizing antibody proteins or for constructing a vector or reagent used to humanize or express an antibody.

Field of Use
Licensee’s lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), an innovative and validated cancer target.

Sphingomabâ„¢ is the original mouse version of this monoclonal antibody.

IPSCIO Record ID: 279976

License Grant
Licensor hereby grants to Licensee through the period and subject to the limitation on the number of Antigens, the right to receive for each Antigen designated by Licensee, a nonexclusive, worldwide license under the Licensor Licensed Patents to make, have made, use, import, offer to sell and sell Antibodies pursuant to a Licensor License Agreement. This right shall not extend to the Licensor Named Antigens.  The rights of Licensee under the Licensor License Agreements shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable Licensor License Agreement.  Each license elected by Licensee hereunder shall be pursuant to a separate Licensor License Agreement and effective as of the date of execution by both parties.
License Property
Antigen means a target molecule, usually a protein, to which an Antibody specifically binds and includes all epitopes on that target molecule.

Antibody means any antibody directed against an Antigen and shall include, without limitation, monospecific and bispecific antibodies (but a separate license shall be required for the antigen involved for each arm of  a  bispecific antibody); less than full-length antibody forms such as Fv, Fab, and F(ab)2; single-chain antibodies; and antibody conjugates bound to a toxin, label or other moiety.  The term 'Antibody' shall include any and all such constructs directed against any particular Antigen.

(a) U.S. Patent No. 4,816,567 and the claims relating to chimeric antibodies found in patents or patent applications arising from divisionals, continuations or continuations-in-part of any application from which U.S. Patent No. 4,816,567 claims priority or any substitute applications therefor, any patent issued with respect to any such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent  as well as the foreign counterparts of the foregoing and any and all reissues, reexaminations or extensions of the foregoing (but in any event excluding U.S.S.N. 07/205,419 and foreign counterparts thereof) ('Chimera Patents') and (b)  any patent issuing based on U.S.S.N. 07/205,419 (a continuation of the application maturing into U.S. Patent No. 4,816,567) relating to the coexpression of immunoglobulin chains in recombinant host cells, as well as the divisionals, continuations or continuations-in-part of such U.S.S.N. 07/205,419.

4,816,567 – Recombinant immunoglobin preparations

Field of Use
Herceptin[R] (trastuzumab) is a humanized anti-HER2 antibody for the treatment of breast cancer.

IPSCIO Record ID: 279903

License Grant
Licensor hereby grants to the Swiss Licensee a co-exclusive license (together with Licensor), under the Licensor Technology, to develop Licensed Products in the Collaborative Fields with respect to the U.S. Territory and the European Union, in accordance with the Asthma Development Plan and Transplant Development Plan, and to import and use Licensed Products for such purposes. The foregoing licenses include the right to perform Development outside the U.S. Territory and European Union in accordance with the Asthma Development Plan and Transplant Development Plan with respect to any Licensed Product, solely in order to obtain Regulatory Approval of such Licensed Product in the Collaborative Fields in the U.S. Territory or the European Union.

Licensor hereby grants to Licensee a co-exclusive (together with Licensor), non-transferable right to Promote and Detail Licensed Products in the Asthma Field in the U.S. Territory, in accordance with applicable law and the Asthma Commercialization Plan.

License Property
Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab, but excluding Nutley Dac.  Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name “Daclizumab” by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.  IL-2R means the IL-2 receptor.

Transplant Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation. In any event, if a given indication satisfies the criteria for both an Autoimmune Indication and a Transplant Indication, such indication shall be deemed a Transplant Indication and not an Autoimmune Indication, provided that an Autoimmune Indication shall not be deemed a Transplant Indication merely because it may cause the need for a transplant (e.g., Type I diabetes, even if it causes the need for an organ transplant).

Licensor Technology means Licensor Know-How and Licensor Patents.

Field of Use
Collaborative Field (i.e., used in the singular) shall refer either to the Asthma Field (unless and until the Asthma Field is excluded from the definition of Collaborative Field or the Transplant Field (unless and until the Transplant Field is excluded from· the definition of Collaborative Field.

Asthma Field means the treatment and/or prevention of asthma or other respiratory diseases.

Transplant Field means the Transplant Indications.

IPSCIO Record ID: 116563

License Grant
Pursuant to the master agreement, each Antigen will have its unique patent agreement.  Licensor grants to Licensee with respect to four (4) Antigens), the rights upon written notice to receive licenses under the Patent Rights for up to four (4) Antigens designated by Licensee.

Each license shall be a nonexclusive, worldwide license under the Licensors Patent Rights to make, have made, use, import, market, promote, offer for sale and sell or otherwise dispose of Antibodies pursuant to a Licensors License Agreements. The rights of Licensee shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable License Agreement.

License Property
The licensed patents are for Humanized Immunoglobulins and Polynucleotides Encoding.

The Antigens are target molecules to which an Antibody specifically binds and includes all epitopes on that target molecule.

The licensed product means an Antibody with respect to which Licensee has either significant marketing rights or has done significant development, including without limitation created, humanized or conducted preclinical or clinical development, the manufacture, import, use, offer to sell or sale of which would infringe, if not licensed under this Agreement, also known as a Valid Claim.

Field of Use
Licensee identifies and develops therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of immunology, infectious diseases and cancer.  Monoclonal antibodies are genetically engineered antibodies that target a specific foreign substance, or antigen.

IPSCIO Record ID: 385688

License Grant
Licensor grants under the Licensor Technology, Collaboration Inventions, and all patents claiming Collaboration Inventions, a co-exclusive license, together with Licensor, to develop in accordance with the Development Plan and use Licensed Products in the Asthma Field with respect to U.S. Territory and the European Union, a co-exclusive license, together with Licensor, to import Licensed Products in the Asthma Field into the European Union for such Development purposes, an exclusive license to import, offer for sale and sell Licensed Products in the Asthma Field in the U.S. Territory, and an exclusive license to make Licensed Products in the Asthma Field in the Territory.

For Additional Licenses to Collaboration Inventions, Licensor grants, under the Collaboration Inventions and all patents claiming Collaboration Inventions a co-exclusive license to develop, make, use, import, offer for sale and sell products, other than Licensed Products or Excluded Products, containing antibodies that bind to IL-2R in the Asthma Field in the Territory; and a co-exclusive license to develop, make, use, import, offer for sale, and sell Licensed Products and other products containing antibodies that bind to IL-2R, other than Excluded Products, in Licensee’s Exclusive Field in the Territory.

For the Trademark License, Licensor grants the co-exclusive right and license, together with Licensor to use the Zenapax Trademark solely in connection with the development, use, marketing, promotion, and detailing of Licensed Products in the Asthma Field in the U.S. Territory, the co-exclusive right and license, together with Licensor, to use the Zenapax Trademark solely in connection with the development of Licensed Products in the Asthma Field with respect to the European Union, and the exclusive right and license to use the Zenapax Trademark solely in connection with the offer for sale and sale of Licensed Products in the Asthma Field in the U.S. Territory.

License Property
Licensor currently markets a humanized antibody against the interleukin-2 (IL-2) receptor Daclizumab, under the trademark Zenapax®.

Autoimmune Indications or Al means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active nonpathogenic hepatitis, non-infectious uveitis (Behcets), aplastic anemia, regional nonpathogenic enteritis (including ulcerative colitis, Crohns Disease and inflammatory bowel disease), Kawasakis disease, post-infectious encephalitis, multiple sclerosis, and tropic spastic paraparesis.

Oaclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name Daclizumab by the United States Adopted Names Council. Oaclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.

Licensed Product shall mean any pharmaceutical product having as an active ingredient Oaclizumab.

Zenapax Trademark means the trademark Zenapax®, and all trademark registrations and applications therefor, and all goodwill associated therewith.

Field of Use
Zenapax (daclizumab), a Phase II humanized monoclonal antibody for moderate to severe asthma.   “Asthma Field” means the treatment and/or prevention of asthma or other respiratory diseases.

The Exclusive Field means, with respect to Licensor, Licensors Exclusive Field and, with respect to Licensee, Licensees Exclusive Field.

Licensors Exclusive Field means the Transplant Indications, Notwithstanding the foregoing, upon the first to occur of the Reversion Effective Date or the Put Right Effective Date, the term Licensors Exclusive Field shall have no meaning.

Licensee’s Exclusive Field means the Autoimmune Indications, excluding the Asthma Field, Other Indications and, upon the first to occur of the Reversion Effective Date or the Put Right Effective Date, the Transplant Indications.

IPSCIO Record ID: 391426

License Grant
The Parties are entering into a worldwide collaboration for the joint development and commercialization of Daclizumab for the treatment of asthma and other respiratory diseases.

In the U.S. Territory
— For the Technology License, Licensor grants a co-exclusive license, together with Licensor, under the Licensor Technology, to develop Licensed Products in the Asthma Field with respect to the U.S. Territory and the European Union, in accordance with the Development Plan, and to import and use Licensed Products for such purposes.  The foregoing licenses include the right to perform Development outside the U.S. Territory and European Union in accordance with the Development Plan with respect to any Licensed Product solely in order to obtain Regulatory Approval of such Licensed Product in the Asthma Field in the U.S. Territory or the European Union.
—  Promotion Right, Licensor grants a co-exclusive, together with Licensor, non-transferable right to Promote and Detail Licensed Products in the Asthma Field in the U.S. Territory during the Co-Promotion Term, in accordance with applicable law and the Commercialization Plan.

In the ROW Territory
— For the Technology License, Licensor grants the exclusive, even as to Licensor, license, under the Licensor Technology, to develop Licensed Products in the Asthma Field in the ROW Territory, other than the European Union, to use and import Licensed Products in the Asthma Field in the ROW Territory, other than the European Union, for such Development purposes, offer for sale and sell Licensed Products in the Asthma Field in the ROW Territory, to use and import Licensed Products in the Asthma Field in the ROW Territory for such commercialization purposes; provided, however, that the license granted with respect to the Queen Patents shall be nonexclusive.

For the Trademark License, Licensor grants the exclusive right and license to use the Licensor Trademarks solely in connection with the development, use, marketing, promotion, detailing, offer for sale and sale of Licensed Products in the Asthma Field in the ROW Territory; provided, however, that Licensee’s license shall be co-exclusive, together with Licensor, with respect to Development in the European Union.

For the Commercialization by Licensee in ROW Territory, except as expressly set forth, Licensee shall have sole responsibility and decision-making authority for the marketing, promotion, sale and distribution of the Licensed Product in the Asthma Field in the ROW Territory.

License Property
Licensor has acquired all rights to Zenapax, excluding transplantation indications but with the option to gain such indication rights by 2007.

Licensor Technology includes ownership of the Licensor Inventions, Know-How and Patents.

Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab.

Collaboration Inventions means all inventions that relate to or are useful with antibodies that bind the IL-2 receptor (IL-2R) and are made during the term of this Agreement by employees of Licensee or persons contractually required to assign or license patent rights covering such inventions to Licensee, in the course of performing Licensee’s obligations, or exercising Roche’s rights, under this Agreement.

Autoimmune Indications or Al means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active nonpathogenic hepatitis, non-infectious uveitis (Behcets), aplastic anemia, regional nonpathogenic enteritis (including ulcerative colitis, Crohns Disease and inflammatory bowel disease), Kawasakis disease, post-infectious encephalitis, multiple sclerosis, and tropic spastic paraparesis.

Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name Daclizumab by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.

Zenapax Trademark means the trademark Zenapax®, and all trademark registrations and applications therefor, and all goodwill associated therewith.

Field of Use
The Exclusive Field means, with respect to Licensee, Licensees Exclusive Field and, with respect to Licensee, Licensees Exclusive Field.

Licensors Exclusive Field means the Autoimmune Indications, excluding the Asthma Field.

Licensees Exclusive Field means the Transplant Indications.

IPSCIO Record ID: 344592

License Grant
Licensor grants a non­exclusive license under Licensed Patents during the Term to make, and have made, use, sell, offer for sale, and import Licensed Product in the Territory in the Field of Use.
License Property
Licensor owns and controls certain patent rights relating to methods and compositions in the field of antibodies.

Chimera Patents shall mean U.S. Patent 4,816,567, and any claims directed to chimeric antibodies or any method of making or using chimeric antibodies, which claims are found in any patents issuing from divisionals, continuations, or continuations-in-part of any application, any claims directed to chimeric antibodies or any method of making or using chimeric antibodies.

Field of Use
The license pertains to certain intellectual property rights covering methods and processes for producing antibodies used in connection with the development of our PS-targeting program.

Licensee is developing, and intends to commercialize, antibody products that bind to the antigen phosphatidylserine (PS) and wishes to acquire a non-exclusive license for such products under the Licensed Patents.

IPSCIO Record ID: 279326

License Grant
Licensor hereby grants to Licensee (a) through the period and subject to the limitation on the number of Antigens provided, the right to receive for each Antigen designated by Licensee, a nonexclusive, worldwide (except as provided in this license under the Licensor Licensed Patents to make, have made, use, import, offer to sell and sell Antibodies pursuant to a Licensor License Agreement.  This right shall not extend to the Licensor Named Antigens.  The rights of Licensee under the Licensor License Agreements shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable Licensor License Agreement.  Each license elected by Licensee hereunder shall be pursuant to a separate Licensor License Agreement and effective as of the date of execution by both parties.
License Property
Licensor Licensed Product means an Antibody with respect to which Licensor either has significant marketing rights or has done significant development (e.g., created, humanized or conducted preclinical or clinical development), the manufacture, import, use, sale or offer to sell of which would infringe, if not licensed under this Agreement, one or more claims of a Licensee Licensed Patent which have neither expired or have been disclaimed nor have been held invalid or unenforceable by a court or other body of competent jurisdiction from which no appeal has been or may be taken.

Antigen means a target molecule, usually a protein, to which an Antibody specifically binds and includes all epitopes on that target molecule.

Antibody means any antibody directed against an Antigen and shall include, without limitation, monospecific and bispecific antibodies (but a separate license shall be required for the antigen involved for each arm of  a bispecific antibody); less than full-length antibody forms such as Fv, Fab, and F(ab)2; single-chain antibodies; and antibody conjugates bound to a toxin, label or other moiety.  The term 'Antibody' shall include any and all such constructs directed against any particular Antigen.

Licensee Licensed Patents mean the following patents and patent applications known generally as the Cabilly patents and patent applications
(a) U.S. Patent No. 4,816,567 and the claims relating to chimeric antibodies found in patents or patent applications arising from divisionals, continuations or continuations-in-part of any application from which U.S. Patent No. 4,816,567 claims priority or any substitute applications therefor, any patent issued with respect to any such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent  as well as the foreign counterparts of the foregoing and any and all reissues, reexaminations or extensions of the foregoing (but in any event excluding U.S.S.N. 07/205,419 and foreign counterparts thereof) ('Chimera Patents') and (b)  any patent issuing based on U.S.S.N. 07/205,419 (a continuation of the application maturing into U.S. Patent No. 4,816,567) relating to the
coexpression of immunoglobulin chains in recombinant host cells, as well as the divisionals, continuations or continuations-in-part of such U.S.S.N. 07/205,419, the issued foreign counterparts of such U.S.S.N. 07/205,419 and
any and all reissues, reexaminations or extensions or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent ('Coexpression Patents').
4,816,567 – Recombinant immunoglobin preparations

Licensor Licensed Patents means the patents and patent applications identified and including any applications filed as of the Effective Date in the United States or any foreign jurisdiction.  Licensed Patents shall include U.S. or foreign patents or patent applications which claim priority to any application to which a listed U.S. patent also claims priority.  Licensor Licensed Patents shall also include any foreign equivalents, addition, continuation, continuation-in-part or division of such patents or patent applications or any substitute applications therefor, any patent issued with respect to any such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent.  

5,693,089 – Method of collapsing an implantable appliance
5,693,761 – Polynucleotides encoding improved humanized immunoglobulins
5,693,762 – Humanized immunoglobulins

Field of Use
This agreement pertains to  Herceptin (transtuzumab).  Herceptin is an intravenous drug that is part of a chemotherapy regimen that is used to prevent recurrence of breast cancer, and for the treatment breast cancer that has spread beyond the breast (metastasized). It belongs to a class of drugs called monoclonal antibodies.

IPSCIO Record ID: 243460

License Grant
The Irish Licensor grants to the Licensee of England a worldwide, non-exclusive, non-transferable license, solely on its own behalf and on behalf of any Licensee Collaborator, without any right to sublicense, under the Licensor Patent Rights to
(a) Make or have made Licensed Antibody Phage Display Materials;
(b) Solely for Research and Development purposes, conduct Antibody Phage Display;
(c) Make or have made Research Quantities of a Licensed Immunoglobulin;
(d) Transfer Antibody Phage Display Materials, Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Licensee Collaborator; and
( e) Use, sell, offer to sell, import and export Licensed Immunoglobulins.
License Property
The patents include Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use, and, Modular Assembly of Antibody Genes, Antibodies, and, Novel Plasmid Vector with Pectate Lyase Signal Sequence.

Antibody Phage Display means the authorized use of Licensed Antibody Phage Display Materials to conduct Research and Development.

Licensed Antibody Phage Display Materials means any collection or library of polynucleotide sequences, including without limitation a Licensee Library, created by Licensee and under the exclusive control of Licensee, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage, including without limitation a Licensee Library, created by or under the exclusive control of Licensee, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin and an outer surface polypeptide of a bacteriophage.

Licensed Immunoglobulin means any Immunoglobulin discovered, isolated or characterized by Licensee or a Licensee Collaborator through the use of Licensed Antibody Phage Display Materials.

Field of Use
The field is antibody drug discovery.

IPSCIO Record ID: 243414

License Grant
Licensor grants an exclusive license under the Technology and Patents to make, have made, import, use, offer for sale, and sell Licensed Product for use in the Field.  The license granted shall include the right to grant a sublicense to one Sublicensee in each country.
License Property
Licensor owns certain patent rights and technology relating to Anti-CD4 Monoclonal Antibodies.
Field of Use
The field shall mean the manufacture, use, importation, offer for sale or sale of Licensed Product for human use only, including therapeutic, prophylactic and diagnostic use.

5A8 is a humanized anti-CD4 monoclonal antibody that is in preclinical development for treatment of human immunodeficiency virus, or HIV. The virus enters the host cell by binding to the CD4 receptors on these cells. In lab studies, our 5A8 antibody binds to the CD4 receptor on the cell surface and prevents viral entry into the cell, thereby blocking infection.

IPSCIO Record ID: 210376

License Grant
Licensor grants a nonexclusive license under the Licensor Patent Rights limited to the Field and Territory, including the right to grant sublicenses, to make, import, have made, use or sell Licensed Products.
License Property
Licensed Products shall mean an Antibody for which Licensee has undertaken significant development efforts, such as conducted or sponsored a human clinical trial, which product is an Antibody that binds to RSV.
Field of Use
The Field is that of human prophylaxis and therapy.  Patent related to a humanized antibody directed against respiratory syncytial virus (RSV) which causes infection of the lungs and breathing passages.

IPSCIO Record ID: 230756

License Grant
For the Patent License For Commercialization of Products, Licensor grants a worldwide, exclusive license or sublicense, in the Field, under Licensor Patents and Licensors interest in Joint Patents, with the right to grant sublicenses, to make, have made, use, import, and offer for sale and sell Products.

For the Know-how License, Licensor grants to
– an exclusive worldwide license to use Licensor Know-how within the Field, wherein such Know-how is solely related to the Collaboration Inhibitor including but not limited to the non-clinical development, process development, manufacturing, clinical development, and marketing of a Collaboration Inhibitor, in pursuance of the Research & Development Plan, during the Collaboration Term, and during the remaining Term of this Agreement.
– a non-exclusive worldwide license to use Licensor Know-how within the Field, wherein such Know-how is related to a Collaboration inhibitor including but not limited to the non-clinical development, and marketing of a Collaboration Inhibitor, in-pursuance of the Research & Development Plan, during the Collaboration Term, and during the remaining Term of this Agreement.

License Property
The patents include but are not limited to Methods and Compositions for the Treatment of  Inflammatory Diseases; Methods and Compositions for the Treatment of glomerulonephritis and other Inflammatory Diseases; Use Of C5-Specific / Antibodies For Reducing Immune And Hemostatic Dysfunctions During Extracorporeal Circulation; Recombinant DNA Products And Methods; and, Single Polypeptide Chain Molecules.

The Collaboration Inhibitor means the humanized anti-C5 monoclonal antibody coded h5G 1.1-ScFv and analogs, derivatives and formulations thereof owned or otherwise Controlled by Licensor.

Field of Use
The Field means the research, development, commercialization and use of Collaboration Inhibitor.  The field of competition is considered any pharmaceutical compound or product that specifically inhibits the production of C5a or specifically inhibits interaction with its receptor and in either case which is developed for use in acute cardiovascular conditions and/or applications and which is not a Product.

IPSCIO Record ID: 203270

License Grant
The English Licensor grants (i) a non-exclusive worldwide sublicense, with the right to grant further Sublicenses, under the Licensed Patent Rights to make, have made, use, import, offer for sale, and/or sell Licensed Products; and (ii) an exclusive worldwide license, with the right to grant Sublicenses, under the Licensors Intellectual Property, to make, have made, use, import, offer for sale, and/or sell Licensed Products.

Licensee shall be entitled to grant further non-exclusive Sublicenses to its Licensees to make, have made, use, import, offer for sale, and/or sell Licensed Products.

License Property
The Licensed Product shall mean a product comprising a Humanised Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensors Intellectual Property or Inventions, not including chimeric antibodies or murine antibodies.

The patents are for Recombinant DNA Products and Methods and Multichain Polypeptides or Proteins and Processes for their Production.

Licensor has genetic engineering expertise to modify murine antibodies wherein certain regions of the immunoglobulin are changed from mouse to human, which modification is sometimes, in one aspect, referred to as humanising or humanisation.

The Antibody are either Antibody IN-NO1 or Antibody IN-C02 and Antibodies shall mean both Antibody IN-NO1 and Antibody IN-C02.

Field of Use
Two companies have entered into an agreement under which Licensor will use its proprietary technology and advanced know-how to humanize Intellect's beta-amyloid specific, monoclonal antibodies for the treatment of Alzheimer's disease. The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer's toxin, beta-amyloid, where it accumulates and causes devastating damage to victims of the disease. Humanization is an essential step in making antibodies safe for use in humans.

IPSCIO Record ID: 280819

License Grant
For the Research the German Licensor grants a non-exclusive research license under Licensor Background Inventions and Licensors rights in Collaboration Data, Collaboration Materials and Collaboration Inventions, to perform its obligations under the Collaboration Plan.

For the Commercial License,  Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.

License Property
Licensors HuCAL Technologies shall mean the HuCAL library and associated technologies.   The library data is for a Design of Human Combinatorial Antibody Library-Fab (HuCAL-Fab).
Field of Use
The field shall mean all therapeutic indications.  With this agreement, the Parties will collaborate in the discovery and development of human monoclonal antibodies against certain specified Licensee Targets,  to generate and characterize antibodies and optimize those antibodies and  use their expertise in developing antibodies in pre-clinical and clinical settings.

The two companies will collaborate on the development of human antibodies for the treatment of cancer.

IPSCIO Record ID: 260370

License Grant
The Regents grants to the Licensee a license under its rights in and to Patent Rights to make, have made, use, Sell, offer for Sale and import Licensed Products and to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

License Property
The Certain inventions are generally characterized as
—  High Affinity Human Antibodies to Novel Tumor Antigens;
—  Bi-specific Single Chain Fv scFv Antibody Molecule; and,
—  Human Erb-B Antibodies.
Field of Use
The Field of Use means use as a therapeutic or diagnostic in humans. The Field of Use specifically excludes providing Licensed Services to third parties; the Sale, transfer, lease, exchange or other disposition or provision of Biological Materials, other than as incorporated in Licensed Products for Sale or as expressly permitted in this Agreement; the making, using or Selling of Biological Materials or Licensed Products for use in drug discovery or as a research reagent (other than for the development of Licensed Products);  the making, using or Selling of Non-Patent Products; and (v) all other uses and applications of Biological Material or Licensed Products, except as expressly permitted in this Agreement.

IPSCIO Record ID: 256276

License Grant
The Licensor of England grants to Licensee of Germany a nonexclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Field.
License Property
Licensor is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development.

Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.

The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.

Field of Use
The Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the Target. Target means the whole or part and natural variants of the granulocyte-macrophage colony stimulating factor (GM-CSF) identified by the SWISS-PROT entry name CSF2_HUMAN and accession number P04141 with the amino acid sequence which is specifically recognized by an Antibody binding to the foregoing.

Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.